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ATTITUDES TOWARD FERTILITY AND FERTILITY PRESERVATION IN  
 
WOMEN DIAGNOSED WITH GLIOMA 
 
 
RACHEL STINER 
ABSTRACT 
Background: Gliomas are the most common primary brain malignancy, with more 
than 16,000 patients diagnosed every year (Ostrom, et al., 2015). Outcomes vary 
widely depending on tumor grade and treatment, and have been steadily improving 
with the advent of new therapeutics. Glioma patients frequently undergo 
chemotherapy to remove residual tumor after surgery, and many of these cytotoxic 
therapies are known to affect rapidly dividing cells such as ovarian follicles 
(Vassilakopoulou et al., 2016). The negative effects of chemotherapy on fertility 
have been demonstrated in patients with breast and colorectal cancer (Bines, et al., 
1996; Avastin Prescribing Information). Additionally, infertility has been linked 
with decreased quality of life, primarily in women (O’Moore et al., 1983; Greil, 
1997). Fertility treatments are available for women undergoing cancer treatment, 
however it is unknown whether these treatments are routinely discussed with 
glioma patients before initiating chemotherapy. 
Objective: The primary goal of this study was to assess whether female glioma 
patients are being effectively counselled on their possible loss of fertility and their 
choices for fertility treatment prior to beginning chemotherapy. To this end, it was 
also important to understand the barriers preventing patients from obtaining 
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information related to their fertility. Another principle goal of this study was to 
describe the effects of chemotherapy on a sample of women with glioma. Finally, 
this study sought to understand the priorities of women with glioma in regards to 
family planning, and to address these priorities in the context of a comprehensive 
fertility preservation discussion. 
Methods: To assess these endpoints, a survey was designed and delivered to 
patients being treated at the Neuro-oncology clinic of the University of California, 
San Francisco. Eligible candidates were identified prior to a clinic visit, and patients 
were asked whether they would like to participate in the survey. Consenting 
patients then completed the survey at home or in the clinic. Seventy two women 
completed the survey. Data was analyzed using STATA Software Version 10.0. 
Results: Analysis of the survey results showed that only 35% of women receiving 
chemotherapy reported having a discussion regarding fertility preservation prior to 
beginning treatment. Of those who reported having this discussion, only 80% were 
aware that chemotherapy could negatively affect their fertility. Many women 
reported that while fertility preservation was not important to them at the time of 
diagnosis, it was a priority for them at the time of survey completion. Most women 
surveyed expressed a desire to have a fertility preservation discussion with a 
reproductive specialist. 
Conclusions: The data obtained in this study suggest a lack of understanding of the 
negative effects of chemotherapy which may be addressed with a more 
comprehensive fertility discussion with glioma patients prior to beginning 
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treatment. Although interest in having children tends to decrease after cancer 
treatment, the majority of respondents still report wanting a child after treatment. 
The priorities of women in the study reflect a concern for the health of their future 
offspring which may be best addressed prior to beginning treatment in order to 
increase their chances of conceiving at a later date. 
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INTRODUCTION 
Gliomas are the most prevalent primary brain malignancy 
 Gliomas are tumors arising from the glial, supportive cells of the brain. The 
vast majority (80%) of all primary brain malignancies are gliomas. Classification of 
these tumors is most commonly done by the World Health Organization (WHO) 
grading system, which grades tumors from Grade I (best prognosis) to Grade IV 
(worst prognosis) based on tumor histology (“Tumor Grading and Staging”). Grade I 
and II tumors are considered to be “Low Grade Gliomas”, and Grade III and IV 
tumors are considered to be “High Grade Gliomas”. Using the WHO grading system, 
several features are taken into account to determine a tumor’s grade: atypical cells, 
mitoses, endothelial proliferation, infiltration and necrosis. If a tumor contains none 
of these characteristics, it is classified as a Grade I (benign) glioma. Grade I gliomas 
do not have infiltrative features and are the only type of glioma that may be “cured” 
by surgery alone. Tumors that contain one of these characteristics are classified as 
Grade II and they are considered malignant. Finally, tumors that contain two or 
more of the above characteristics are classified as Grade III or IV and considered 
high grade (Grier, 2006). 
 In adults, gliomas may be subdivided into astrocytomas, olidodendrogliomas, 
or mixed oligoastrocytomas depending on the cell type of origin. Ependymomas are 
a fourth type of glioma that are relatively rare, making up only 2-3% of primary 
brain tumors (“Ependymoma”).  
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 Grade II gliomas usually display hypercellularity, but do not contain areas of 
necrosis. These tumors make up approximately 15% of all primary gliomas, and 
tend to afflict patients aged 20-50, carrying a median survival rate of 5-7 years 
(Pouratian & Schiff, 2010; Aijian & Recht, 2014). 
 Grade III gliomas, in addition to displaying hypercellularity, are more 
pleomorphic in character, and cells of these tumors exhibit a wide range of 
variability in the size and shape. The mean age of onset for grade III gliomas is 45 
years, and median survival time for patients with anaplastic astrocytoma is 3-4 
years (Pan & Prados, 2003; Stupp et al., 2005). 
 Grade IV gliomas, also called glioblastomas (GBM) are the most common, 
accounting for 55% of primary brain tumors. These tumors have a higher labelling 
index than grade III tumors, corresponding to a faster rate of cell division and more 
aggressive growth (Pan & Prados, 2003). The mean age of onset of GBM is 54 years 
(Pan & Prados, 2003). Median survival time for individuals with GBM is 
approximately 14.6 months if the patient receives standard radiation and 
chemotherapy (Stupp et al., 2005).  
 Although tumor grade is an important prognostic factor, other factors that 
are essential to consider are age at onset, tumor location, extent of resection, and 
treatment (Edge & AJCC, 2010). In addition, presence or absence of molecular 
markers is an important component of understanding a patient’s tumor. The 
presence of a certain molecular marker may make a patient more likely to respond 
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to a particular therapy. For this reason, molecular studies are often performed 
immediately after resection, and may contribute to prognosis. 
 
Standard treatment for glioma includes surgery, radiation, and chemotherapy 
 Regardless of tumor grade and histopathology, the first course of treatment 
is almost always maximal safe surgical resection of the tumor. Exceptions are made 
in some low grade cases when resection may not confer a clear benefit, or when a 
tumor is deep-seated or in an eloquent area that increases risk of postoperative 
neurological deficits (Raizer & Parsa, 2015). It has long been shown that extent of 
resection correlates with increased overall survival, increased progression-free 
survival and, in the case of low grade gliomas, increased time to malignant 
transformation. However, the infiltrative nature of gliomas prevents a true 
“complete removal” of the tumor through surgery alone (McGirt et al., 2009). 
Surgical removal not only reduces mass effect (pressure and swelling, causing 
symptoms) but enables a pathological examination of the tumor tissue, which helps 
inform clinical decision-making.  
 Radiation is considered the best treatment method following surgery. 
Although it carries its own risks of toxicity, radiation confers an advantage over 
systemic chemotherapy that side effects other than fatigue are localized to the tissue 
being irradiated (Lutz et al., 2007) Once the gross tumor volume is determined, a 
clinical target volume which includes areas of subclinical infiltrative disease is 
defined. Radiation oncologists will then determine a planning target volume which 
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allows for a margin of error (Burnet, 2004). Patients are usually treated with 
multiple “fractions” of radiation, which has been shown to be more effective than 
one large single dose or a few large doses (Lutz et al., 2007). The goal of 
radiotherapy is to target as much of the tumor as possible without affecting the 
surrounding healthy tissue. However, some healthy tissue is unavoidably affected 
and side effects of this stray radiation include necrosis, edema, cognitive decline, 
motor deficits, and personality changes (Veninga et al., 2001). Edema can often be 
managed with the use of corticosteroids (Veninga et al., 2001).  Because glioma 
radiation treatment is localized to the affected brain area, side effects associated 
with whole body radiation, such as damage to early responding tissues like the 
ovaries and uterine lining, are not observed. 
 In many cases, radiation may be given concurrently with chemotherapy. The 
current standard of care for GBM is 6,000 cGy of radiation given over 30 days along 
with concurrent temozolomide (TMZ) and six months of adjuvant temozolomide 
(Raizer & Parsa, 2015). Temozolomide is an alkylating agent that attaches a methyl 
group to the purine bases of DNA. Because TMZ is a systemic therapy that targets 
rapidly dividing cells, it commonly causes gastrointestinal toxicity due to the highly 
proliferative nature of the gastrointestinal lining. This type of therapy also causes 
damage to bone marrow leading to low white blood cell counts. In a study of 300 
glioma patients, nausea, vomiting, and anorexia were shown to be the most common 
side effects of TMZ (Bae et al., 2014). There is also evidence that TMZ may cause 
damage to ovarian follicles (see below).  
 5 
 Another common therapy used in treatment of both low and high grade 
gliomas is the combination of procarbazine, lomustine (CCNU), and vincristine - 
shortened to “PCV”. Both procarbazine and CCNU are alkylating agents similar to 
TMZ. Vincristine is a vinca alkaloid which works by preventing chromosome 
separation during mitosis, leading to cell death. Like alkylating agents, vincristine 
targets rapidly dividing cells and causes many of the same side effects. 
 Bevacizumab is a monoclonal antibody which blocks growth of new blood 
vessels to tumor tissue. It is commonly used to treat recurrent glioblastoma, either 
as a monotherapy or in combination with another chemotherapeutic agent. 
Common side effects associated with bevacizumab are proteinuria and hypertension 
(Gilbert et al., 2014). Bevacizumab is used to treat other types of cancer besides 
glioma, notably kidney and colon cancer. Recently a study of patients with colorectal 
cancer suggested that bevacizumab may cause premature ovarian failure in female 
patients, and this warning has been added to the prescribing information for the 
drug (Avastin Prescribing Information). 
 
Some cancer treatments affect patients’ ability to reproduce 
 The ability to conceive is dependent on the health of the ovaries, uterus, 
hypothalamic-pituitary axis, and overall health of the body. Cancer itself, radiation 
therapy, and cytotoxic treatments can impair the health of any of these systems. 
Some studies report that up to half of women experience menstrual cessation with 
cancer treatment (Goodwin et al., 1999). Amenorrhea is the complete loss of 
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menses, while oligomenorrhea is defined as light or infrequent menstrual periods. 
While normal menses do resume in some women after treatment, others continue to 
experience amenorrhea or oligomenorrhea. Even the resumption of normal menses 
does not guarantee fertility, as up to 40% of women who resumed their menstrual 
cycle after cytotoxic treatment were found to be infertile (Vassilakopoulou et al., 
2016). 
 Premature ovarian failure (POF) is the loss of ovarian function before the age 
of 40, due either to a lack of ovarian follicles or a failure of primordial follicles to 
mature (Daan et al., 2015). The ovaries of women with POF show cortical fibrosis, 
deformation of capillaries supplying follicles, and in some cases defects in mature 
follicles. Cytotoxic drugs can cause POF by impeding cell division or by causing 
direct damage to mature follicles (Vassilakopoulou et al., 2016). While other rapidly-
dividing areas may recover after cessation of cytotoxic treatments, the ovaries are 
unable to do so (Falcone et al., 2004).  
 Many chemotherapeutic agents have been implicated in causing POF. In a 
study of patients with colorectal cancer, 34% of female patients being treated with 
bevacizumab showed ovarian failure during treatment versus only 2% of female 
patients on the same regimen without bevacizumab. After cessation of treatment, 
22% of female patients treated with bevacizumab recovered ovarian function as 
determined by resumption of a menstrual cycle, a positive pregnancy test, or 
demonstration of low FSH serum level (Avastin Prescribing Information). However, 
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these indicators alone do not give information on the health of the ovarian follicles 
or the number of follicles remaining.  
 Alkylating agents including temozolomide and CCNU have also been linked to 
POF.  Taking into account the mechanism of action of these drugs, which is to 
alkylate newly copied DNA, it is unsurprising that they affect rapidly-dividing cells 
such as ovarian follicles. A study of patients who underwent treatment for childhood 
cancer found that those treated with CCNU or other alkylating agents were 
significantly less likely to have been pregnant than patients who were not treated 
with alkylating agents (Green et al., 2009). However, at least one study has shown 
that the gonadotoxic profile of TMZ is less severe than that of other alkylating agents 
such as cyclophosphamide or busulfan (Sitruk et al., 2010). 
 Patient age is also directly linked with increased risk of POF, with one study 
showing that among patients receiving chemotherapy, those greater than 40 years 
old had significantly higher rates of amenorrhea than those age 40 and younger 
(Bines, Oleske & Cobleigh, 1996). Since the number of remaining ovarian follicles 
declines steeply with age, older women are at a higher risk for permanent ovarian 
failure. 
 
Infertility is associated with decreased quality of life 
 Infertility is commonly defined as the inability to conceive after trying to do 
so for one year. Several studies have sought to examine the effects of infertility on 
quality of life, although the results of these studies considered together are 
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somewhat equivocal. Some studies have shown that infertile patients are more 
likely than their fertile peers to experience psychological distress, sensitivity, and 
depression (O’Moore et al., 1983). While other studies evaluating personality 
disorders in these patients have showed ambiguous results, it is generally accepted 
that infertile patients do experience increased distress in comparison to fertile 
controls. It is also well known that infertility causes more stress in female patients 
than it does in male patients  (Greil, 1997). 
 
Fertility preservation methods are available 
 
 Options do exist for women who would like to take steps to preserve their 
fertility prior to undergoing radiation or chemotherapy. In vitro fertilization (IVF) 
involves stimulating the ovaries, collecting the mature oocytes, and immediately 
fertilizing them in vitro before freezing. This method, while one of the most 
established and successful, has the downside of requiring sperm immediately after 
harvesting the oocytes. Therefore, it is not always a viable option for single women 
who wish to conceive later in life. In vitro fertilization also requires 10-14 days for 
follicular development, which may not be possible for patients needing to undergo 
chemotherapy immediately (Levine, Canada & Stern, 2010; Vassilakopoulou et al., 
2016). 
 Another option that is more amenable to single women is mature oocyte 
cryopreservation. Using this method, the ovaries are stimulated to produce mature 
follicles, which are then harvested and frozen. While success rates of mature oocyte 
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cryopreservation are lower than embryo cryopreservation, this method is becoming 
more successful and up to 60% of oocytes can be expected to survive the thawing 
process at a later date. Of those oocytes that successfully thaw, roughly 33% to 50% 
will be successfully fertilized and implanted (Chen, 1986). 
 For women who require immediate chemotherapy following diagnosis, there 
are two options currently available, although both are less studied and established 
than traditional IVF methods. One option is harvesting immature oocytes rather 
than mature oocytes and freezing until fertilization is desired. While this procedure 
may be done immediately (without the 10-14 day delay), it also carries a lower 
success rate than mature oocyte preservation (Suikkari, 2008). 
 Finally, an emerging method of fertility preservation is ovarian tissue 
freezing and grafting. Using this method, either an entire ovary or part of an ovary is 
removed laparoscopically and frozen after being sliced thinly. After the patient has 
undergone treatment for their cancer and has recovered to an acceptable state, the 
tissue is grafted onto the existing ovary or the uterine wall. This method ensures the 
availability of numerous follicles and can also be performed without the 10-14 delay 
in treatment (Gook et al., 2005; Oktay et al., 1997). 
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SPECIFIC AIMS 
 
It is estimated that in 2015 alone, there were over 16,000 new cases of 
primary glioma in the United States (Ostrom, et al., 2015). Although it is widely 
accepted that cancer chemotherapy causes gonadotoxicity, these effects have not 
been studied in glioma patients. In addition, it is unknown whether female glioma 
patients are receiving adequate counseling regarding their options for fertility 
preservation, or whether they are even aware that treatment may affect their 
fertility. Some studies have shown that infertility negatively impacts quality of life, 
but the specific priorities and values of glioma patients and how they change due to 
cancer diagnosis or fertility status have not been investigated (Schover et al., 1999). 
This paper seeks to achieve the following aims: 
1. Describe how chemotherapy affects fertility of women with gliomas.  
2. Examine whether female glioma patients are being adequately counseled on 
the possible side effects of chemotherapy on their fertility and their options 
for fertility treatment.  
1. Understand the barriers to communication that may be causing 
inadequate fertility counseling prior to cancer treatment.  
3. Describe the priorities of women diagnosed with glioma regarding family 
planning and future childbearing.  
  
 11 
METHODS 
Study Population and Eligibility 
 In order to assess the fertility outcomes, priorities, and effectiveness of 
fertility counseling in women with glioma, we used data collected from the “Fertility 
in Women with Primary Brain Malignancies” study conducted at the University of 
California, San Francisco (UCSF). This study was approved by the UCSF Institutional 
Review Board and was designed to analyze fertility in women with glioma, as well 
as understand whether these patients were receiving adequate counseling 
regarding fertility treatment prior to undergoing treatment for their cancer. 
Eligible patients were women between the age of 18-45 at time of diagnosis 
who had a primary brain malignancy that was WHO grade II, III, or IV. Potentially 
eligible women were identified at check-in prior to their visit at the UCSF Neuro-
oncology clinic. These patients were then given a description of the study and, if 
interested, were consented in clinic by a trained researcher. Consented patients 
were then given the link to the online study, which they could choose to complete 
either after their clinic visit at a provided computer terminal or at home at their 
leisure. Patients were also given the option to complete the survey on an iPad 
provided to them in the clinic, or to complete the survey in paper format at home or 
at the clinic. If participants had not completed the survey prior to returning to the 
clinic for a second visit, they were reminded to do so. A final reminder was given at 
the third visit if the participant had failed to complete the survey. Surveys were 
completed between October 27, 2010 and December 5, 2013. This survey was cross-
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sectional in nature; women completed the survey at different time points after their 
diagnosis and during their treatment. 
Of 99 women consented to the study, 73 completed the study either in paper 
or digital format. Of these, one patient gave responses only to the initial 
demographic information, and did not provide responses to any of the questions in 
the body of the survey. This patient’s data was not included in the analysis.  
 
Effect of Chemotherapy on Fertility 
 
 One of the primary aims of the survey was to analyze the effect of 
chemotherapy on patient fertility.  This was done using a targeted set of questions 
that investigated whether patients had tried to have a child after completing cancer 
treatment and if they had successfully conceived. Patients were also asked whether 
fertility treatment was used and if so, which methods were utilized. Additionally, 
patients were asked to report changes in their menstrual cycles that occurred since 
cancer treatment began.  Unfortunately, there were complications with questions 
designed to assess the effect of chemotherapy on fertility leading to a lack of data in 
this area. Few women reported attempting to conceive after treatment and among 
these women there was low response toward questions assessing their fertility. One 
notable exception is the assessment of menstrual changes since treatment initiation, 
and the results of this data will be discussed.  
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Determination of Prevalence and Effectiveness of Fertility Counseling 
 
 Several survey questions were designed to understand the circumstances 
surrounding pre-treatment fertility preservation discussions. Patients were asked 
whether they had a discussion regarding fertility preservation prior to treatment, 
and if so, who initiated the discussion. Patients also answered questions regarding 
which parties participated in the discussion, and with whom they would have felt 
most comfortable discussing the topic. Lastly, patients reported whether or not they 
were aware that chemotherapy could affect their fertility.  
 
Priorities of Women with Glioma 
 
 One of the goals of the project was to understand the priorities of women 
with glioma in relation to family planning and childbearing and how these priorities 
were influenced by their diagnosis. We asked women to rank the following 
categories in order of importance both before their diagnosis and after their 
treatment: having a child, spending time with loved ones, career, hobbies, health, 
and service. Women were asked to give a priority of 1 (most important) to 6 (least 
important), and they were also allowed to give a “tie” to two or more categories. 
Since patients only completed the survey once, and only after their treatment was 
initiated, they were asked to recall their priorities prior to diagnosis to the best of 
their abilities. 
 In order to more precisely understand the desires and concerns of women 
regarding family planning and childbearing, we asked participants to rank a series 
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of statements based on how desirable they were. Women gave a rank of 0 (not 
desirable) to 10 (most desirable thing imaginable) for 18 statements relating to 
being pregnant and having a child.  
 Similarly, women were asked to rank the undesirability of 17 statements 
relating to aspects of pregnancy and motherhood. Participants ranked statements 
from 0 (desirable) to 10 (most undesirable thing imaginable). Rankings for both 
categories (desirable and undesirable) were independent of one another and the 
same score could be assigned to multiple statements. 
 Finally, women were asked to indicate how strongly they agreed or disagreed 
with six statements regarding feelings toward having a first child or an additional 
child. Rankings were given on a scale of 0 (strongly disagree) to 10 (strongly agree).  
 
Statistical Analysis 
 
 Survey results were analyzed using STATA Software Version 10.0. 
Descriptive statistics including age at diagnosis, tumor grade, and parity were 
generated. A chi-square test was performed to test the hypothesis that interest in 
having more children did not change before diagnosis to after treatment, regardless 
of the patient’s tumor grade.  
 Data regarding fertility discussions was tabulated and described. A chi-
square test was performed to test the correlation between tumor grade and 
awareness that treatment affected fertility.  
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Priorities before diagnosis and after treatment were analyzed and described. 
Average scores for each category were calculated, and the difference between the 
averages was determined. A t-test was performed for each category to test the 
hypothesis that there was no difference in the average. Average ranking of 
desirability or undesirability for each category was calculated and data was ordered. 
Data was evaluated qualitatively to understand general desires and concerns of 
women regarding childbearing.  
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RESULTS 
Description of the Variables in the Study Population 
  
Demographics 
 
 Seventy two women between the ages of 19 and 45 completed the survey 
between 2010 and 2013. The average age of women completing the survey was 35.3 
years old, and the median age was 36 years. Among the study population, 78% 
identified as White, 7% identified as Hispanic, 6% identified as Asian, 1% identified 
as African American, and 8% identified as either “more than one race” or “other”. 
One person declined to state their race. The majority of women taking the survey 
were in some type of relationship, either married (48%), living with their partner 
but not married (14%) or significantly involved but not living with their partner 
(9%). The remainder of the women reported that they were either single (25%) or 
separated (4%).  
 
Tumor Grade and treatment 
 
Grade 2 gliomas were the most prevalent, representing 49% of those 
surveyed. Grade 3 gliomas were the second most common, accounting for 33% 
followed by grade 4 gliomas (GBM) representing 15% of the sample. Two 
participants noted a grade of “other”. It is possible that women reporting a grade of 
“other” were those who had experienced a progression of their tumor grade (i.e. 
their tumor had progressed from grade 3 to 4 during treatment). It is also possible 
that these women had grade I tumors, although the survey was designed to exclude 
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women with grade I tumors after this step. In analyses that consider tumor grade, 
participants reporting a grade of “other” were not considered. The vast majority 
(89%) of subjects reported receiving surgery for their tumor, while 75% received 
chemotherapy, 57% received radiation, 13% received all of the treatments listed 
plus others. One person declined treatment for their tumor. 
 
Childbearing and Fertility 
 
Participants were asked to report the number of children that they had at the 
time of taking the survey. The majority of the participants (57%) were nulliparous 
(never having given birth), while 18% had one child, 17% had two children, and 8% 
had three, four, or five children. Participants were asked if they were infertile before 
they were diagnosed with cancer, however only 21 subjects responded to this 
question. Five participants (24%) responded that they were infertile, 13 
participants (62%) responded that they were not infertile, and 3 participants (14%) 
reported that they had never tried to conceive. Descriptive statistics are given in 
Table 1. 
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Table 1. Descriptive Statistics of the Study Population. The mean and standard 
deviation are defined for the continuous variables. The frequency (n) and percent 
are defined for categorical variables.  
Characteristic (n=72) Mean (SD) or n (%) 
Age (years) 35.3 (7.06) 
Ethnicity  
   White, Non-Hispanic 56 (78%) 
   Hispanic/Latino 5 (7%) 
   African-American/Black 1 (1%) 
   Asian 4 (6%) 
   Other 6 (8%) 
Relationship Status  
   Single 18 (25%) 
   Significantly Involved but Not Living    
with Partner 
6 (9%) 
   Living with Partner but Not Married 10 (14%) 
   Married 34 (48%) 
   Separated 3 (4%) 
Tumor Grade  
    2 35 (49%) 
    3 24 (33%) 
    4 11 (15%) 
  Other 2 (3%) 
Parity  
   Nulliparous 41 (57%) 
   Primiparous 13 (18%) 
   Multiparous 18 (25%) 
Number of children 0.82 (1.17) 
Cancer treatments received (multiple 
responses allowed) 
 
   Surgery 64 (89%) 
   Chemotherapy 54 (75%) 
   Radiation 41 (57%) 
   All of the above plus others 9 (13%) 
   No treatment 1 (1%) 
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Effect of Cancer Treatments on Fertility 
Self-reported infertility  
 Women were asked questions regarding their fertility before diagnosis and 
after treatment in order to understand changes that may have occurred due to 
chemotherapy. Of the 21 women who responded, 5 (23%) reported that they were 
infertile prior to diagnosis, 13 (62%) reported they were not infertile, and 3 (14%) 
reported they had not attempted to conceive prior to diagnosis. In addition, four 
women reported that they received fertility treatment prior to diagnosis, with all 
four receiving hormonal treatments, and two receiving intrauterine sperm 
injections. 
 Only four women reported trying to conceive after completing treatment. Of 
these women, one was unable to conceive while three did successfully conceive. The 
unsuccessful patient reported trying to conceive for 10-12 months and did not 
report using any method of fertility treatment for assistance.  
Menstrual changes 
 In order to understand the frequency of menstrual changes after treatment, 
participants were asked questions about their menstrual cycle before and after 
undergoing treatment for their cancer. Of the women who responded, only 6% of 
women reported having irregular menstrual cycles prior to treatment, while 91% 
reported regularity and the remaining 3% did not remember. Participants were 
then asked to describe how their menstrual cycle had changed since undergoing 
therapy. Subjects chose one answer that best matched their experience out of 
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thirteen options which included increases and decreases in frequency, changes in 
amount of bleeding, and changes in menstrual patterns. Of the 59 women who 
provided a response and who had begun treatment, 56% reported some type of 
menstrual change since initiating cancer treatment, while 36% reported no change. 
The remaining 8% reported that they either did not know or their response did not 
fit into one of the categories defined. Of those patients who had chemotherapy, 69% 
reported some type of change to their menstrual cycle, while only 22% of women 
who did not have chemotherapy (but who may have had surgery and/or radiation) 
reported a change. A chi-square analysis showed that this was significant with 
p=0.009, indicating a correlation between being treated with chemotherapy and 
experiencing menstrual changes.  
 
Determination of Prevalence and Effectiveness of Fertility Counseling 
 
 A central goal of the study was to assess whether fertility counseling was 
made available to patients prior to their initiation of any cancer treatments, and to 
identify any obstacles preventing this discussion. Participants were asked whether 
they discussed fertility preservation prior to beginning treatment, and only 30% 
reported that they had. Approximately 61% reported not having a fertility 
preservation discussion, and 9% did not remember whether they had discussed it. 
However, of those who received chemotherapy, 35% stated that they had a fertility 
preservation discussion, while only 17% of patients that did not receive 
chemotherapy reported having this discussion. This result was not statistically 
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significant with p=0.10. This may reflect the small sample size, or may indicate that 
those undergoing chemotherapy were not in fact more likely to discuss fertility 
preservation. In this sample, patients with grade 2 gliomas were statistically less 
likely to have had a fertility preservation discussion than patients with grade 3 or 4 
gliomas (p=0.015), however these patients were also statistically less likely to have 
undergone chemotherapy (p=0.004).  
Patients were also asked whether they knew that cancer treatments could 
affect their fertility, and 63% reported awareness of this fact. Of those patients who 
had a fertility discussion, 80% were aware of the risks to their fertility. However, 
among patients who did not have a fertility discussion, only 55% were aware of the 
risks posed by chemotherapy. A chi-square analysis was performed to analyze 
whether patients were more likely to be aware that treatments affected their 
fertility if they had a fertility preservation discussion and this result approached 
significance at p=0.054. In order to determine whether patients were more likely to 
be aware of treatment effects on their fertility if they had a higher grade tumor, a 
chi-square test was performed and the results were statistically significant with 
p=0.01. While only 47% of participants with grade 2 tumors were aware, 77% of 
those with grade 3 tumors were aware, and 90% of those with grade 4 tumors 
reported awareness. This result was still significant after controlling for whether 
individuals had undergone chemotherapy (p=0.02). 
Several follow-up questions were asked of the 21 patients who reported 
having this discussion in an attempt to better understand the counselling that did 
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occur. Patients were asked who brought up the issue of fertility preservation, and 
52% reported that their doctor brought it up, 33% reported that their family 
member brought up the issue, and 52% reported that they themselves raised the 
discussion (options were not mutually exclusive). This subset of patients was 
further asked to report with whom they had this fertility preservation discussion, 
and again options were not mutually exclusive. Patients were most likely to engage 
in the conversation with their oncologist, followed by their gynecologist, 
reproductive specialist, nurse, and social worker (Table 2). One patient reported 
having the discussion, but not remembering with whom it occurred, and another 
patient reported that they had the discussion with another health professional not 
listed. Most patients who had this discussion reported that they would have felt 
most comfortable having the discussion with a reproductive specialist (62%), 
however a sizable group reported that they would have preferred discussing 
fertility preservation with their oncologist (38%). 
To better understand the barriers women faced in having a discussion 
regarding their fertility, participants were asked why they did not initiate a 
discussion with their doctor and thirty eight women provided responses. Fourteen 
women (37%) reported that fertility preservation was not important to them, even 
at the time of taking the survey, while 21 (55%) women reported that fertility 
preservation was not important to them initially but was important at the time of 
the survey. One (3%) woman reported that she was embarrassed to initiate the 
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discussion with her doctor, while three (8%) women were concerned with taking up 
their doctor’s time for this discussion.  
Table 2. Details of the Fertility Discussion.  Responses to fertility discussion 
questions are tabulated below. The number of participants responding to each 
question is listed in the right column. 
Variable Mean (SD) or n (%) 
Prior to treatments, was fertility preservation 
discussed? 
N=69 
   Yes 21 (30%) 
   No 42 (61%) 
  I Don’t Know/I Don’t Remember 6 (9%) 
If yes, who brought up the discussion? N=21 
   Doctor 11 
   Family Member 7 
   Patient 11 
If yes, with whom did you have the discussion? N=21 
    Oncologist 17 
    Gynecologist 7 
    Reproductive Specialist 6 
    Nurse 2 
   Don’t Remember 1 
   Other 1 
With whom would you have felt most 
comfortable having the discussion? 
N=21 
   Oncologist 8 (38%) 
   Reproductive Specialist 13 (62%) 
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Priorities of Women with Glioma Regarding Childbearing and Family Planning 
Another major goal of the study was to evaluate the priorities of women 
diagnosed with glioma, and to understand how these priorities affected their 
decisions regarding fertility preservation and childbearing. Women were asked 
whether they were interested in having more children both before diagnosis and 
after treatment. Women were more likely to report wanting more children before 
their diagnosis (54%), versus after their diagnosis (35%). Women were more likely 
to report that they were not interested in having children after their treatment, with 
28% responding negatively versus only 16% responding negatively prior to 
diagnosis. However, they were also more likely to report that they were 
“considering” having more children, with 33% responding in this manner versus 
only 21% of subjects giving this response prior to diagnosis. A comparison of the 
answers given before diagnosis and after treatment is given in Table 3. The subset 
of patients who gave responses both before diagnosis and after treatment and 
answered either “yes” or “no” were evaluated separately and a chi-square test 
revealed a significant difference in proportion of response (Table 4). 
Table 3. Interest in Having More Children. Responses to the question “Are you 
interested in having more children?” either before diagnosis or after treatment are 
tabulated below. The sample size for each question is listed in each column. 
Response Before Diagnosis (n=71) After Treatment (n=40) 
Yes 38 (53.5%) 14 (35%) 
No 11 (15.5%) 11 (27.5%) 
Considering 15 (21.1%) 13 (32.5%) 
Hadn’t thought about it 7 (9.9%) 2 (5.0%) 
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Table 4. Interest in Having More Children, Subset. Responses to the question 
“Are you interested in having more children?” either before diagnosis or after 
treatment are tabulated below for those who answered either “yes” or “no” at both 
time points.  
Response Before Diagnosis (n=34) After Treatment (n=34) 
Yes 29 (85%) 23 (68%) 
No 5 (15%) 11 (32%) 
 
Participants were also asked to rank six categories in order of importance 
before diagnosis and after treatment, with 1 representing the most important item 
and 6 representing the least important item. On average, women reported that 
“Spending time with loved ones” was their top priority both prior to diagnosis and 
after receiving treatment. On average, this category became even more important 
after treatment, however this change was not statistically significant. T-tests were 
conducted to evaluate the change in average ranking for each category prior to 
diagnosis and after treatment, and four changes were significant with p<0.05. 
“Having a child” and “Career” both became less important with average changes of 
0.51 points and 0.81 points, respectively. Both “Health” and “Service” became more 
important, with average changes of 0.84 and 0.31 respectively. On average, 
“Hobbies” became slightly more important after treatment, however this change 
was not statistically significant. Average changes in importance and the p-values for 
these t-tests are given in Table 5. 
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Table 5. Average Ranking of Priorities. Category rankings on a 1-6 scale were 
averaged over the study population. The difference between each average ranking 
before diagnosis and after treatment was tabulated and a t-test was performed to 
test whether this difference was significant. Each average is listed along with the 
difference between averages and the associated p-value. Significant p-values are 
bolded. 
Response Before 
Diagnosis  
After 
Treatment  
Average 
Difference 
(SD) 
P value of T-
Test 
Having a Child 3.7 (1.9) 4.3 (1.8) -0.51 (2.0) 0.024 
Spending Time 
with Loved 
Ones 
2.2 (1.4) 2.0 (1.2) 0.23 (1.2) 0.103 
Hobbies 4.2 (1.1) 4.2 (1.1) 0.05 (1.2) 0.7419 
Career 3.0 (1.6) 3.8 (1.4) -0.81 (1.8) 0.0003 
Health 2.8 (1.4) 2.0 (1.3) 0.84 (1.5) 0.0001 
Service 4.8 (1.4) 4.4 (1.2) 0.31 (1.2) 0.0265 
 
Participants were asked to give ratings of desirability from 0 to 10 for 
eighteen categories centering around having a child. Zero represented an 
undesirable outcome, while ten represented the most desirable outcome 
imaginable, and these rankings were not mutually exclusive (i.e. a participant could 
rank every category as “10” if they desired). Of the eighteen categories, the most 
highly rated was “having a family” with an average rating of 7.2 closely followed by 
“experiencing a close bond between myself and my child” with an average rating of 
7.0. The lowest rated items were “providing my parents with grandchildren” 
(average rating of 4.5) and “feeling more complete as a woman through having a 
baby” (average rating of 4.0). The complete list of average ratings is given in Table 6.  
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Table 6. Ratings of Desirability. Participants were asked to rate the desirability of 
the following categories on a scale of 0 (least desirable) to 10 (most desirable). 
Average ratings were computed and sorted. 
Characteristic Mean (SD) 
Having a Family 7.16 (3.68) 
Experiencing a close bond between myself and my child 6.99 (3.61) 
Guiding and teaching my child 6.99 (3.55) 
Seeing my baby’s own personality emerge 6.64 (3.71) 
Holding and cuddling a baby 6.09 (3.71) 
Devoting myself to raising children and being a mother 5.94 (3.96) 
Having a son or a daughter 5.76 (3.88) 
Being physically connected to my baby for 9 months 5.43 (3.74) 
Being able to get pregnant 5.34 (3.89) 
Giving my partner the satisfaction of being a parent 5.31 (3.75) 
Feeling a baby move and kick inside me 5.27 (3.75) 
Seeing family resemblance 5.20 (3.71) 
Giving birth to a baby 4.86 (4.03) 
Having companionship through a child 4.86 (3.50) 
Breastfeeding a baby 4.85 (3.79) 
Having a child who will carry out my family tradition 4.64 (3.62) 
Providing my parents with grandchildren 4.53 (3.62) 
Feeling more complete as a woman through having a baby 4.00 (3.84) 
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In addition to rating desirable items, participants were asked to rate the 
“undesirability” of seventeen items on a scale of 0 to 10, with 10 being the most 
undesirable score. As before, ratings for these items were not mutually exclusive. On  
average, the most undesirable item was having a “child with a genetic disease” with 
a rating of 8.9. The second most undesirable item was “having a baby who is born 
deformed” with a rating of 8.9. The least undesirable items (items that women were  
not as concerned about) were “feeling responsible for another person’s life” and 
“being kept away from a career by a child” with ratings of 3.7 and 4.0 respectively. 
The most undesirable items tended to center around having a child with poor health 
or leaving a child without a parent. The full list of ratings is given in Table 7.  
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Table 7. Ratings of Undesirability. Participants were asked to rate the 
undesirability of the following categories on a scale of 0 (least undesirable) to 10 
(most undesirable). Average ratings were computed and sorted. 
Characteristic Mean (SD) 
Having a child with a genetic disease 8.93 (2.11) 
Having a baby who is born deformed 8.91 (2.12) 
Worrying about effects of chemo/radiation on embryo formation 8.77 (2.11) 
Becoming pregnant during a recurrence 8.71 (2.35) 
Leaving a child behind without a parent(s) 8.69 (2.49) 
Guilt of possibly leaving a child 8.69 (2.39) 
Passing off negative genetic traits or diseases 8.60 (2.42) 
Having a baby who strains my health 7.19 (2.63) 
Feeling guilty or inadequate as a parent 6.45 (3.29) 
Having a child who is a burden to my partner 6.24 (3.42) 
Burden on finances 5.51 (3.07) 
Experiencing the pain of childbirth 5.31 (3.57) 
Taking care of a sick child 5.17 (3.29) 
Experiencing the discomforts of pregnancy 4.97 (3.44) 
Having a baby who takes away my freedom to do other things 4.43 (3.48) 
Being kept away from a career by a child 4.00 (3.36) 
Feeling responsible for another person’s life 3.66 (3.35) 
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DISCUSSION 
 
General limitations of the study 
 
 The survey format of the study posed several limitations to the quantity and 
quality of data that could be extracted. For instance, patients completed the survey 
at one time after their cancer diagnosis and were asked to answer questions 
regarding their state of mind before their diagnosis. In particular, women were 
asked to recall the regularity of their menstrual cycles, their priorities regarding 
childbearing and family planning, and whether they had a fertility discussion. All of 
this data could be influenced by inaccurate memories due to the time elapsed 
between the time periods in question and taking the survey. It should also be noted 
that in some cases brain tumor causes memory impairment, and this may have led 
to difficulty in accurately completing the questionnaire for some patients. There was 
substantial nonresponse in some areas of the survey, which prevented accurate 
evaluation of many of the primary questions that were raised. This nonresponse 
may have been due to the sheer length of the survey, which consisted of 71 
questions (many with multiple parts). Patients may have also felt discomfort 
towards portions of the survey that asked about sensitive topics, or they may have 
elected not to answer a question if they were unable to clearly recall information. 
 In addition to the length of the survey, there was also some redundancy 
present in the survey questions. This redundancy led to difficulty in accurately 
interpreting data, and necessitated the removal of some areas of interest from the 
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final analysis. A shorter, more succinct and targeted survey may have yielded higher 
response and less ambiguity. 
 
Effect of Cancer Treatments on Fertility 
 While one of the primary goals of the study was to evaluate how cancer 
treatment affects the fertility of women with glioma, we were not able to answer 
this question with a substantial degree of confidence due to significant nonresponse 
in this area of the survey. It is possible that women who were not attempting to 
have children did not respond to questions regarding fertility, even though there 
was an option to indicate this on the survey. Additionally, participants were not 
asked to consent to a medical chart review, which prevented verification of this and 
other data. 
 We also attempted to understand infertility in our sample by the indirect 
means of evaluating changes in menstrual cycle. Data showed that some type of 
change in menstrual cycle was very common among participants, especially among 
those who underwent chemotherapy. While change in menstrual cycle does not 
necessarily indicate loss of fertility, research has shown a correlation between 
women who experience menstrual changes during chemotherapy and those who 
report infertility. The extent to which menstrual changes were reported suggests a 
serious risk to fertility within our sample. 
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Determination of Prevalence and Effectiveness of Fertility Counseling 
 Women who had not undergone chemotherapy for their tumor were less 
likely to report having a fertility discussion than those who had. This is consistent 
with the understanding that the greatest threat to fertility for brain cancer patients 
is chemotherapy. Targeted brain irradiation is unlikely to cause damage to distant 
tissues. Therefore, a physician would not necessarily need to educate their patient 
about possible loss of fertility if the patient was only receiving some combination of 
surgery or radiotherapy. Within the subset of patients who underwent 
chemotherapy for their brain tumor, we found that only 35% recalled having a 
discussion regarding fertility risks and preservation with their physician. Even 
taking into account the fact that this number may be low due to recall bias, this 
statistic is alarming. Since all common chemotherapy treatments pose a risk to 
fertility, any patient receiving these therapies should be given information notifying 
them of these risks. It is possible that physicians do broach this subject with 
patients, but do so when they are still recovering from the initial shock of being 
given a brain tumor diagnosis. If this is the case, it may be best to delay this 
discussion until after patients have had time to process their diagnosis and are 
receptive to more information regarding their tumor and possible treatments. 
Interestingly, more patients reported being aware that treatments could affect their 
fertility than reported having a fertility discussion. This may indicate that patients 
are finding this information on their own using outside resources. Because outside 
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resources can vary in source and accuracy, they should be reinforced by information 
from a medical professional caring for the patient. 
 The survey results also indicated that 80% of those who do report having a 
fertility discussion are aware that treatment may affect their fertility. This result is 
encouraging as it demonstrates that discussions are somewhat effective and may 
help patients make educated choices regarding preserving their fertility prior to 
treatment. The 20% of women who do not report awareness despite having a 
fertility discussion may represent those patients for which these risks need to be 
reiterated.  
 The results also showed that the higher the grade of tumor a patient had, the 
more likely they were to be aware of the detrimental effects of treatment, even 
controlling for whether individuals underwent chemotherapy (p=0.02).  
 While most patients reported having a fertility preservation discussion with 
their oncologist, patients also indicated they would be most comfortable having this 
discussion with a reproductive specialist. This disparity may indicate that patients 
are interested in receiving more specific information regarding their fertility 
options, and that referrals to a reproductive specialist should be standard. 
 An important finding in the study was that 21 women reported that they did 
not bring up the topic of fertility preservation because it was not important to them 
at the time of diagnosis, but was important to them at the time of being surveyed. 
This discrepancy may be caused by many factors: patients being overwhelmed by 
the implications of their new diagnosis, not being aware that infertility is an issue, or 
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not planning on children at the time of diagnosis. The fact that the proportion of 
women wanting children decreases after diagnosis indicates that this is probably 
not the cause of the discrepancy. Instead, it is likely that patients are overwhelmed 
by their new diagnosis and undereducated to the risks of cancer treatment on their 
fertility, causing them to neglect initiating this discussion with their physician 
before undergoing treatment.  
 
Priorities of Women with Glioma regarding childbearing and family planning 
 Results of the survey showed that women were less likely to report wanting 
another child after treatment than before their diagnosis. In addition, women report 
that health becomes more important after treatment while having children loses 
some importance. These results show a shift of priorities toward taking care of self 
versus planning for a family. 
 In reviewing the ratings of “desirability” and “undesirability” given to topics 
of family planning and childrearing, a few patterns emerge. The most highly 
undesirable items tend to be those that pertain to either passing health problems 
onto offspring or leaving children without a parent. It is unclear whether the women 
surveyed were concerned that their tumor may be an indicator of poor health in 
their children, or that treatment would affect the genetic health of their gametes. In 
either case, it is clear that patients have concerns regarding the health of their future 
offspring, and these concerns may be addressed in a comprehensive fertility 
discussion. The worry of leaving a child without a parent may explain some of the 
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decrease in desire to have children after tumor treatment as opposed to prior to 
diagnosis. 
Suggestions Going Forward 
Suggestions for clinicians are based on the principal results of this study: 
 Only 35% of women receiving chemotherapy for their glioma recall having 
had a conversation regarding fertility preservation prior to initiating 
treatment. 
 Only 80% of those who had a fertility preservation discussion reported 
awareness that treatment could affect their fertility. 
 A substantial proportion of respondents reported that while fertility 
preservation was not important to them at the time of diagnosis, it was 
important to them at a later date. 
 Most women surveyed desired to speak with a reproductive specialist about 
fertility preservation methods. 
These data suggest a lack of knowledge from women undergoing cytotoxic 
chemotherapy for their brain tumor in regards to the hazards of this therapy on 
their reproductive health. Furthermore, the results of this survey suggest that 
patients who do have fertility preservation discussions with their doctors may still 
be left with gaps in their understanding. We suggest that a fertility preservation 
discussion be initiated with a patient that is considering chemotherapy before 
treatment begins. It may be best to broach this topic with patients after the initial 
shock of their brain tumor diagnosis subsides in order to increase retention. 
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However, in the setting of a brain tumor diagnosis, immediate treatment is often 
fundamental to prolonging survival. Therefore, it may not be feasible in many cases 
for physicians to have this discussion with their patients at a later date. It may also 
be helpful to have this conversation in the presence of the patient’s caregiver 
(spouse or family member) if they are available. 
It may also be in the patient’s best interest to offer a referral to a 
reproductive specialist so that patients may gain a complete understanding of the 
risks to their fertility and their options to circumvent this risk. However, insurance 
may not pay for a consultation with a fertility expert, let alone fertility preservation 
procedures themselves. These are all issues that must be assessed on a case-by-case 
basis taking into account the patient’s priorities and the healthcare available to 
them. 
 We believe that this survey itself increased awareness of fertility issues 
among neuro-oncologists at our institution (University of California, San Francisco). 
In addition, the field of neuro-oncology is evolving to encompass issues of fertility 
and of quality of life after tumor treatment due to the increased life expectancy of 
patients in the last decade. These changes in the field may lead to an improvement 
in fertility outcomes and general quality of life of brain cancer patients in the future. 
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